PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

An evaluation of Wb123 antibody elisa in individuals treated with ivermectin and albendazole, and implementation challenges in Africa.

Abstract The development of antibody testing for the diagnosis of lymphatic filariasis (LF) is intended to enhance the monitoring and evaluation activities of the Global Program for the Elimination of LF. This is due to the fact that antibody tests are expected to be the most sensitive at detecting exposure to LF compared to antigen that takes longer to develop. To this end a new antibody-based enzyme linked immunosorbent assay (ELISA) to Wuchereria bancrofti antigen Wb123 has been developed and further designed into a point of care rapid diagnostic test, under evaluation. In pre-treatment surveys, individuals were tested for antigen using the immuno-chromatographic test (ICT) card, and night blood microfilariae, after which all positives were treated using Ivermectin and Albendazole. The Wb123 ELISA was tested in antigen positive individuals, three months after they were treated. Samples were also tested for ICT and night blood microfilariae. The results revealed a reduction in microfilariae and ICT prevalence after treatment. Antigen and antibody prevalence increased with age. However, there was no correlation with the antibody responses observed. The mean WB123 antibody titers were higher among ICT positives, but not significantly different from ICT negative persons. While the Wb123 is targeted for use in untreated populations, further evaluations and guidelines will be required to define its use in populations that have undergone treatment for the control of LF.
PMID
Related Publications
Authors

Mayor MeshTerms
Keywords

Ghana

Lymphatic filariasis

Wb123

antibody

antigen

elephantiasis

Journal Title the pan african medical journal
Publication Year Start




PMID- 28819487
OWN - NLM
STAT- In-Process
DA  - 20170818
LR  - 20170821
IS  - 1937-8688 (Electronic)
VI  - 27
DP  - 2017
TI  - An evaluation of Wb123 antibody elisa in individuals treated with ivermectin and 
      albendazole, and implementation challenges in Africa.
PG  - 65
LID - 10.11604/pamj.2017.27.65.11004 [doi]
AB  - The development of antibody testing for the diagnosis of lymphatic filariasis
      (LF) is intended to enhance the monitoring and evaluation activities of the
      Global Program for the Elimination of LF. This is due to the fact that antibody
      tests are expected to be the most sensitive at detecting exposure to LF compared 
      to antigen that takes longer to develop. To this end a new antibody-based enzyme 
      linked immunosorbent assay (ELISA) to Wuchereria bancrofti antigen Wb123 has been
      developed and further designed into a point of care rapid diagnostic test, under 
      evaluation. In pre-treatment surveys, individuals were tested for antigen using
      the immuno-chromatographic test (ICT) card, and night blood microfilariae, after 
      which all positives were treated using Ivermectin and Albendazole. The Wb123
      ELISA was tested in antigen positive individuals, three months after they were
      treated. Samples were also tested for ICT and night blood microfilariae. The
      results revealed a reduction in microfilariae and ICT prevalence after treatment.
      Antigen and antibody prevalence increased with age. However, there was no
      correlation with the antibody responses observed. The mean WB123 antibody titers 
      were higher among ICT positives, but not significantly different from ICT
      negative persons. While the Wb123 is targeted for use in untreated populations,
      further evaluations and guidelines will be required to define its use in
      populations that have undergone treatment for the control of LF.
FAU - de Souza, Dziedzom Komi
AU  - de Souza DK
AD  - Department of Parasitology, Noguchi Memorial Institute for Medical Research,
      University of Ghana, Ghana.
FAU - Owusu, Irene Offei
AU  - Owusu IO
AD  - Department of Parasitology, Noguchi Memorial Institute for Medical Research,
      University of Ghana, Ghana.
FAU - Otchere, Joseph
AU  - Otchere J
AD  - Department of Parasitology, Noguchi Memorial Institute for Medical Research,
      University of Ghana, Ghana.
FAU - Adimazoya, Michelle
AU  - Adimazoya M
AD  - Department of Parasitology, Noguchi Memorial Institute for Medical Research,
      University of Ghana, Ghana.
FAU - Frempong, Kwadwo
AU  - Frempong K
AD  - Department of Parasitology, Noguchi Memorial Institute for Medical Research,
      University of Ghana, Ghana.
FAU - Ahorlu, Collins Stephen
AU  - Ahorlu CS
AD  - Department of Epidemiology, Noguchi Memorial Institute for Medical Research,
      University of Ghana, Ghana.
FAU - Boakye, Daniel Adjei
AU  - Boakye DA
AD  - Department of Parasitology, Noguchi Memorial Institute for Medical Research,
      University of Ghana, Ghana.
FAU - Wilson, Michael David
AU  - Wilson MD
AD  - Department of Parasitology, Noguchi Memorial Institute for Medical Research,
      University of Ghana, Ghana.
LA  - eng
PT  - Journal Article
DEP - 20170529
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
PMC - PMC5554654
OTO - NOTNLM
OT  - Ghana
OT  - Lymphatic filariasis
OT  - Wb123
OT  - antibody
OT  - antigen
OT  - elephantiasis
EDAT- 2017/08/19 06:00
MHDA- 2017/08/19 06:00
CRDT- 2017/08/19 06:00
PHST- 2016/10/21 [received]
PHST- 2017/03/31 [accepted]
AID - 10.11604/pamj.2017.27.65.11004 [doi]
AID - PAMJ-27-65 [pii]
PST - epublish
SO  - Pan Afr Med J. 2017 May 29;27:65. doi: 10.11604/pamj.2017.27.65.11004.
      eCollection 2017.